Amgen (NASDAQ:AMGN) Releases Earnings Results

Amgen (NASDAQ:AMGN - Get Free Report) posted its earnings results on Thursday. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72, Zacks reports. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same period in the prior year, the company posted $3.96 EPS. The company's revenue for the quarter was up 9.4% on a year-over-year basis. Amgen updated its FY 2025 guidance to 20.000-21.200 EPS.

Amgen Stock Performance

Shares of Amgen stock opened at $281.22 on Friday. The business has a 50-day simple moving average of $299.66 and a 200-day simple moving average of $291.49. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen has a one year low of $253.30 and a one year high of $346.85. The company has a market cap of $151.20 billion, a PE ratio of 37.25, a P/E/G ratio of 2.63 and a beta of 0.51.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is currently 126.09%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. UBS Group reiterated a "neutral" rating and issued a $315.00 target price (down previously from $319.00) on shares of Amgen in a research report on Friday. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Bank of America lifted their price target on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Morgan Stanley reissued an "equal weight" rating on shares of Amgen in a report on Friday. Finally, Citigroup reaffirmed a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $310.22.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the sale, the executive vice president now directly owns 44,186 shares of the company's stock, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last 90 days. 0.69% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amgen

An institutional investor recently raised its position in Amgen stock. Brighton Jones LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,468 shares of the medical research company's stock after purchasing an additional 5,226 shares during the quarter. Brighton Jones LLC's holdings in Amgen were worth $7,159,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.